Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1394-1400

  Liberman, Uli A ^a   Hochberg, M C ^b   Geusens, P ^c   Shah, A ^d   Lin, J ^d   Chattopadhyay, A ^d   Ross, P D ^d  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c HASSELT UNIVERSITY   (Belgium)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; Antiresorptive therapy; Fracture; Hormone therapy; Ibandronate; Osteoporosis; Raloxifene; Risedronate

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; HORMONE; IBANDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33749846272     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01148.x     Document Type: Article

References (30)

1. Johnell O. The socioeconomic burden of fractures: Today and in the 21st century. Am J Med 1997; 103: 20S-6.
2. Epstein S. Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal site. Aging Clin Exp Res 2000; 12: 330-41.
3. Ross PD. Clinical consequences of vertebral fractures. Am J Med 1997; 103: 30S-43.
4. van Helden S, Cals J, Kessels F et.al. Risk of new clinical fractures within 2years following a fracture. Osteoporos Int 2006; 17: 348-54.
5. The Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 496-507.
6. Cranney A, Guyatt G, Griffith L et.al. IX. Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8.
7. Cauley J, Robbins J, Chen Z et.al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA 2003; 290: 1729-38.
8. Women's Health Initiative. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-12.
9. Papapoulos SE, Quandt SA, Liberman UA et.al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468-74.
10. McClung MR, Geusens P, Miller PD et.al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
11. Chesnut CH III, Skag A, Christiansen C et.al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.
12. United States Food and Drug Administration, Center for Drug Evaluation and Research. Application Number 21-455, Boniva Medical Review. http://www.fda.gov/cder/foi/nda/2003/21-455_Boniva_medr_P1.pdf (accessed March 27, 2006).
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
14. Harris ST, Watts NB, Genant HK et.al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999; 282: 1344-52.
15. Reginster JY, Minne HW, Sorensen OH et.al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91.
16. Black DM, Thompson DE, Bauer DC et.al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-24.
17. Cummings SR, Black DM, Thompson DE et.al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
18. Chesnut CH III, Silverman S, Andriano K et.al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109: 267-76.
19. Ettinger B, Black DM, Mitlak BH et.al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45.
20. Hosking D, Geusens P, Rizzoli, R. Osteoporosis therapy: Putting evidence-based medicine into clinical practice. Q J Med 2005; 98: 403-13.
21. Oxman AD, Guyatt GH. A consumer's guide to subgroup analysis. Ann Intern Med 1992; 116: 78-84.
22. Recker R, Kendler D, Recknor C et.al. Effects of raloxifene or alendronate on fracture risk reduction: Results from the EVA (Evista®/Alendronate Comparison) Trial. J Bone Miner Res 2005; 20 (Suppl. 1): S97.
23. Downs RW Jr, Bell NH, Ettinger MP et.al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85: 1783-8.
24. Luckey M, Kagan R, Greenspan S et.al. Once-weekly alendronate 70mg and raloxifene 60mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004; 11: 405-15.
25. Sambrook PN, Geusens P, Ribot C et.al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) international. J Intern Med 2004; 255: 503-11.
26. Johnell O, Scheele WH, Lu Y et.al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 985-92.
27. Hosking D, Adami S, Felsenberg D et.al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomized, placebo-controlled study. Curr Med Res Opin 2003; 19: 383-94.
28. Rosen CJ, Hochberg MC, Bonnick SL et.al. Treatment with once-weekly alendronate 70mg compared to once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized, double-blind study. J Bone Miner Res 2004; 20: 141-51.
29. Nguyen ND, Eisman JA, Nguyen TV. Anti-hip fracture efficacy of bisphosphonates: A Bayesian analysis of clinical trials. J Bone Miner Res 2006; 21: 340-9.
30. Barrett-Connor E, Mosca L, Collins P et.al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.